89. 400 conditions when NOS3 is dirty: “Genopedia: NOS3,” Center for Disease Control and Prevention, Accessed April 2017, https://phgkb.cdc.gov/HuGENavigator/huGEPedia.do?firstQuery=NOS3&geneID=4846&typeSubmit=GO✓=y&typeOption=gene&which=2&pubOrderType=pubD
.90. 400 conditions when NOS3 is dirty: “NOS3,” Mala Cards, Accessed April 2017, http://www.malacards.org/search/results/NOS3
.91. Erectile Dysfunction: Musicki, B., Burnett, AL. “eNOS function and dysfunction in the penis,” Experimental Biology and Medicine, February 2006, https://www.ncbi.nlm.nih.gov/pubmed/16446491/
.92. Runny nose and high blood pressure: Kirchheimer, Sid. “Sniffing Out High Blood Pressure Risk,” WebMD, 18 February 2003, http://www.webmd.com/hypertension-high-blood-pressure/news/20030218/sniffing-out-high-blood-pressure-risk#1
.93. Effects of dirty NOS3 during pregnancy: Leonardo, DP. et al. “Association of Nitric Oxide Synthase and Matrix Metalloprotease Single Nucleotide Polymorphisms with Preeclampsia and Its Complications,” PLoS One, 28 August 2015, https://www.ncbi.nlm.nih.gov/pubmed/26317342
.94. Heart disease increase after menopause: “Hormone replacement therapy and your heart,” Mayo Clinic, 09 July 2015, http://www.mayoclinic.org/diseases-conditions/menopause/in-depth/hormone-replacement-therapy/art-20047550
.95. Lower estrogen after menopause and increased cardiovascular risk: Hayashi, T. et al. “Effect of Estrogen on Isoforms of Nitric Oxide Synthase: Possible Mechanism of Anti-Atherosclerotic Effect of Estrogen,” Gerontology, 15 April 2009, http://www.karger.com/Article/Abstract/213883
.96. Statins stimulate nitric oxide: Cerda, Alvaro et al. “Role of microRNAs 221/222 on Statin Induced Nitric Oxide Release in Human Endothelial Cells,” Arquivos Brasileiros de Cardiologia, March 2015, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386847/
.97. Side effects of statins: “Side Effects of Cholesterol-Lowering Statin Drugs,” WebMD, Acessed April 2017, http://www.webmd.com/cholesterol-management/side-effects-of-statin-drugs#1
.98. Statins ineffective with dirty NOS3: Hsu, CP. et al. “Asymmetric Dimethylarginine Limits the Efficacy of Simvastatin Activating Endothelial Nitric Oxide Synthase,” Journal of the American Heart Association, 18 April 2016, https://www.ncbi.nlm.nih.gov/pubmed/27091343
.99. Nitroglycerin resistance: Münzel, T. et al. “Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability,” Circulation Research, 7 January 2000, https://www.ncbi.nlm.nih.gov/pubmed/10625313
.100. Ineffectiveness of nitroglycerin in smokers: Haramaki, N. et al. “Long-term smoking causes nitroglycerin resistance in platelets by depletion of intraplatelet glutathione,” Arteriosclerosis, Thrombosis, and Vascular Biology, November 2001, https://www.ncbi.nlm.nih.gov/pubmed/11701477
.101. Nitroglycerin and arginine with NOS3: Daiber A., Münzel T. “Organic Nitrate Therapy, Nitrate Tolerance, and Nitrate-Induced Endothelial Dysfunction: Emphasis on Redox Biology and Oxidative Stress,” Antioxidants & Redox Signaling, 10 October 2015, https://www.ncbi.nlm.nih.gov/pubmed/26261901
.102. Arginine steal: Pernow, J., Jung, C. “Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal?” Cardiovascular Research, 1 June 2013, https://www.ncbi.nlm.nih.gov/pubmed/23417041
.103. Bacteria stealing arginine: Cunin, Raymond et al. “Biosynthsis and Metabolism of Arginine in Bacteria,” Microbiological Reviews, September 1986, http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC373073&blobtype=pdf
.104. Arginine ineffective in increasing nitric oxide: Giam, B. et al, “Effects of Dietary l-Arginine on Nitric Oxide Bioavailability in Obese Normotensive and Obese Hypertensive Subjects,” Nutrients, 14 June 2016, https://www.ncbi.nlm.nih.gov/pubmed/27314383
.